Literature DB >> 19025123

Immune complex-mediated cytokine production is regulated by classical complement activation both in vivo and in vitro.

Johan Rönnelid1, Erik Ahlin, Bo Nilsson, Kristina Nilsson-Ekdahl, Linda Mathsson.   

Abstract

Immune complexes (IC) induce a number of cellular functions, including the enhancement of cytokine production from monocytes, macrophages and plasmacytoid dendritic cells. The range and the composition of cytokines induced by IC in vitro is influenced by the availability of an intact classical complement cascade during cell culture, as we have showed in our studies on artificial IC and on cryoglobulins purified from patients with lymphoproliferative diseases. When IC purified from systemic lupus erythematosus sera were used to stimulate in vitro cytokine production, the amount of circulating IC and IC-induced cytokine levels depended both on in vivo classical complement function as well as on the occurrence of anti-SSA, but not on anti-dsDNA or any other autoantibodies. Collectively these findings illustrate that studies on IC-induced cytokine production in vitro requires stringent cell culture conditions with complete control and definition of access to an intact classical complement pathway in the cell cultures. If IC are formed in vivo, the results have to be interpreted in the context of classical complement activation in vivo as well as the occurrence of IC-associated autoantibodies at the time of serum sampling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19025123

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  Alloantibodies prevent the induction of transplantation tolerance by enhancing alloreactive T cell priming.

Authors:  Audrea M Burns; Anita S Chong
Journal:  J Immunol       Date:  2010-12-06       Impact factor: 5.422

2.  The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production.

Authors:  Paul Gallo; Ricardo Gonçalves; David M Mosser
Journal:  Immunol Lett       Date:  2010-07-27       Impact factor: 3.685

3.  Depletion of γδ T Cells Leads to Reduced Angiogenesis and Increased Infiltration of Inflammatory M1-like Macrophages in Ischemic Muscle Tissue.

Authors:  Christoph Arnholdt; Konda Kumaraswami; Philipp Götz; Matthias Kübler; Manuel Lasch; Elisabeth Deindl
Journal:  Cells       Date:  2022-04-29       Impact factor: 7.666

4.  Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.

Authors:  Maria del P Martin; Shaguna Seth; Dimitrios G Koutsonanos; Joshy Jacob; Richard W Compans; Ioanna Skountzou
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

5.  Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.

Authors:  William C Weldon; Bao-Zhong Wang; Maria P Martin; Dimitrios G Koutsonanos; Ioanna Skountzou; Richard W Compans
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

6.  Lipid-dependent cytotoxicity by the lipase PLRP2 and by PLRP2-positive cytotoxic T lymphocytes (CTLs).

Authors:  Bryce N Alves; Kristen Marshall; David L Tamang; Jeffrey Leong; Doug Redelman; Viki Elliott; Mark E Lowe; Dorothy Hudig
Journal:  Cell Biochem Funct       Date:  2009-07       Impact factor: 3.685

7.  Wortmannin, PI3K/Akt signaling pathway inhibitor, attenuates thyroid injury associated with severe acute pancreatitis in rats.

Authors:  Ablikim Abliz; Wenhong Deng; Rongze Sun; Wenyi Guo; Liang Zhao; Weixing Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 8.  Dendritic cells in hepatitis C infection: can they (help) win the battle?

Authors:  Angela Dolganiuc; Gyongyi Szabo
Journal:  J Gastroenterol       Date:  2011-02-17       Impact factor: 6.772

9.  Regulatory roles of the PI3K/Akt signaling pathway in rats with severe acute pancreatitis.

Authors:  Ping Xu; Jing Wang; Zhi-wen Yang; Xiao-li Lou; Cheng Chen
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.